logo
Impact Radar
  • Overview
  • Impact Performance
  • Compare this company
  • All sources
    • Sign UpLog In
    logo

    Genmab | Sustainability & Chart

    DK0010272202

    Basic information on Genmab

    Location: Denmark

    Industry: Health Services

    Website

    knob-globe
    61%

    Impact Score

    Description Genmab

    Genmab A/S is a biotechnology company that specializes in the creation and development of human antibody therapeutics for the treatment of cancer and other diseases.

    Genmab Sustainability Performance

    Renewable Energy
    Greenhouse Gas Emissions
    Supply Chain
    Waste Recycling
    Sustainable [100]
    Almost sustainable [67-99]
    Moderate [34-66]
    Not sustainable [0-33]
    No data
    We measure the sustainability of companies based on 12 criteria.Indicators range from 0 to 100: values from 0 to 33 are shown in red (“not sustainable”), values from 34 to 66 in yellow (“moderate”), values from 67 to 99 in light green (“almost sustainable”), and a value of 100 in green (“sustainable”). Learn more about our method.

    Compare Genmab with ...

    Genmab

    ?

    Impact Score

    knob-globe
    61%
    knob-globe
    0%
    Climate
    Society
    Gender

    Sources of sustainability performance

    MetricValueUnitYearPDF NamePDF Page
    CEO-to-Employee Pay Ratio
    CEO-to-median-salary-ratio64ratio2024Genmab Annual Report 2024.pdf116
    CEO nameJan G. J. van de Winkel2024Genmab Annual Report 2024.pdf77
    Employee turnover rate
    Employee turnover7%2024Genmab Annual Report 2024.pdf114
    Gender Pay Gap
    Unadjusted gender pay gap12%2024Genmab Annual Report 2024.pdf116
    Glass Ceiling
    Women in workforce57%2024Genmab Annual Report 2024.pdf115
    Women in management52%2024Genmab Annual Report 2024.pdf115
    Greenhouse Gas Emissions
    Number of employees2 682Number2024Genmab Annual Report 2024.pdf10
    Scope 1 emissions534(tCO2eq)2024Genmab Annual Report 2024.pdf99
    Scope 2 emissions, location based2 705(tCO2eq)2024Genmab Annual Report 2024.pdf99
    Harassment and Discrimination at the Workplace
    Incident notification mechanismYes2024Genmab_Code of Conduct_2023_EN.pdf7
    Retaliation safeguardsYes2024Genmab Annual Report 2024.pdf127
    Anti-discrimination policyYes2024Genmab Annual Report 2024.pdf109
    Confidentiality mechanismsYes2024Genmab_Code of Conduct_2023_EN.pdf8
    Renewable Energy
    Total renewable energy consumption61%2024Genmab Annual Report 2024.pdf98
    Supply Chain
    Scope 3 emissions187 976(tCO2eq)2024Genmab Annual Report 2024.pdf99
    Scope 1 emissions534(tCO2eq)2024Genmab Annual Report 2024.pdf99
    Scope 2 emissions, location based2 705(tCO2eq)2024Genmab Annual Report 2024.pdf99
    Number of employees2 682Number2024Genmab Annual Report 2024.pdf10
    Union Formation and Collective Bargaining Power
    Number of employees2 682Number2024Genmab Annual Report 2024.pdf10
    Collective bargaining agreements coverage0employees2024Genmab Annual Report 2024.pdf114
    Women on the Board
    Executive board size9Directors2024Genmab Annual Report 2024.pdf115
    Women on supervisory board4Directors2024Genmab Annual Report 2024.pdf115
    Women on executive board3Directors2024Genmab Annual Report 2024.pdf115
    Supervisory board size9Directors2024Genmab Annual Report 2024.pdf115
    Women in Management
    Women in management52%2024Genmab Annual Report 2024.pdf115
    Note: The PDF pages given here refer to the page in the PDF document, which is not necessarily the one found in the footer of the page. For example, page 10 is the 10th page in the document, even if it is labeled as page 8.

    Find more sustainable companies

    logo
    HomeFind Companies & ETFsLearn to investAcademyGlossaryOur Method
    ImprintPrivacy PolicyGTCFAQContact Us
    © 2025 money:care GmbHDisclaimerThe information provided is for informational purposes only and does not constitute an offer, recommendation, or investment advice to buy or sell financial instruments. Nor may they or any part of them be used as a basis for concluding a contract. They have been adopted in good faith from publicly accessible sources. No liability can be assumed for their accuracy. Any financial instrument referred to in this information and documents may be unsuitable for the respective investor to whom it is addressed. The recipients of such information and documents are responsible for independently evaluating and reviewing the products, assets, and financial instruments mentioned therein. Investors must make their own assessment of the suitability of the financial instruments mentioned herein based on the benefits and risks associated with the acquisition of the products, as well as on the basis of their own investment strategy and their legal, tax, and financial situation. Should readers use the content offered or follow any advice, they act on their own responsibility.The source of ETF data is the websites and data sheets of the respective ETF providers.The information contained in the company descriptions is generated by artificial intelligence and is for informational purposes only. While we strive for accuracy, the content may not be entirely reliable or comprehensive. We recommend cross-referencing the AI-generated content with other reliable sources to verify it and gain a more comprehensive understanding of the respective companies.Some links are affiliate links. If you click on these links and open an account, we will receive a small commission. Don't worry, you won't incur any additional costs. Thank you for your support!Logos provided by Logo.dev